Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

BVXVW - Biondvax Pharmaceuticals Ltd Warrants 2015-15.5.20 On Shs

Previous close
7.52
0   0%

Share volume: 0
Last Updated: Wed 13 May 2020 06:00:00 AM CEST
Pharmaceuticals: Major: -0.03%

PREVIOUS CLOSE
CHG
CHG%
$7.52
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
59%
Profitability 75%
Dept financing 25%
Liquidity 25%
Performance 60%
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$7.52
P/E Ratio 
N/A
DAY RANGE
$7.52 - $7.52
EPS 
$0.00
52 WEEK RANGE
$0.11 - $2.16
52 WEEK CHANGE
-$53.12
MARKET CAP 
6.666 M
YIELD 
N/A
SHARES OUTSTANDING 
6.536 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$101
AVERAGE 30 VOLUME 
$294
Company detail
CEO: Ronald Babecoff
Region: US
Website: http://www.biondvax.com
Employees: 0
IPO year: -
Issue type:
Market: NASDAQ
Industry: Pharmaceuticals: Major
Sector: Health Technology

BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases. It works on M-001, a synthetic peptide-based protein targeting both seasonal and pandemic strains of the influenza virus. The company was founded by Ron Babecoff and Rami Epstein on July 22, 2003 and is headquartered in Jerusalem, Israel.

Recent news